Overview
- The peer‑reviewed study published in Nature Communications on 8 July 2026 examined 100 non‑hospitalized people with post‑COVID eye problems and 32 controls, finding symptoms that lasted from three months up to three years and that left about one third of patients on full‑ or part‑time sick leave.
- Standard eye exams often missed the condition, so researchers used high‑resolution microscopy, pupil and eye‑muscle testing, and tear‑fluid proteomics to reveal objective abnormalities.
- Tear‑protein patterns pointed to immune dysregulation involving T cells and signs of nerve injury, while impaired pupil control and eye‑muscle dysfunction explained extreme light sensitivity, headaches, trouble reading, and some cases of adult‑onset strabismus.
- The team produced two diagnostic models—one using instruments found in large eye clinics with about 77 percent estimated accuracy and a second that adds tear‑protein markers and improves accuracy to roughly 91 percent—but neither model is yet in routine clinical use.
- Authors stress the study’s Swedish, modest sample and call for larger, multi‑center research to determine how common the syndrome is, its long‑term outlook, and whether targeted treatments can relieve patients who report major impacts on work and study.